SCHEMBL20947401

SCHEMBL20947401

Cc1nnc(-c2ccc3cnc(NC(=O)N4CC[C@H](N(C)C)[C@@H](F)C4)cc3n2)s1

nearest known ligand 0.76

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 20/20 0.76
DYRK1A Q13627 20/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20949767 0.89 GSK3B (0.75) GSK3BDYRK1A
SCHEMBL20951454 0.89 GSK3B (0.75) GSK3BDYRK1A
SCHEMBL20946827 0.89 GSK3B (0.75) GSK3BDYRK1A
SCHEMBL20951805 0.88 GSK3B (0.75) GSK3BDYRK1A
SCHEMBL20951555 0.88 GSK3B (0.75) GSK3BDYRK1A
SCHEMBL20946870 0.88 GSK3B (0.79) GSK3BDYRK1A
SCHEMBL20947341 0.87 GSK3B (0.73) GSK3BDYRK1A
SCHEMBL20946568 0.86 GSK3B (0.76) GSK3BDYRK1A
SCHEMBL20947813 0.86 GSK3B (0.76) GSK3BDYRK1A
SCHEMBL20916027 0.86 GSK3B (1.00) GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US claimed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US claimed
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US disclosed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DKK1, WNT1 GSK3B 19/4885DYRK1A 1/4885
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof DYRK1A, DKK1, WNT1 GSK3B 19/4885DYRK1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.